Literature DB >> 19179976

Osteoactivin bioinformatic analysis: prediction of novel functions, structural features, and modes of action.

Abdulhafez A Selim1.   

Abstract

BACKGROUND: The initial identification of osteoactivin (OA) came from studies using an animal model of osteopetrosis in rats. Several recent studies suggested roles for OA in osteoblast differentiation, fibroblast differentiation, cancer metastasis, and attenuation of muscle, liver, and kidney injury-induced degeneration. MATERIAL/
METHODS: Several bioinformatic tools were utilized, including ArrayExpress, Pfam, SMART, Prosite, ELM, ProFun, PFP, Consensus Secondary Structure Prediction server, and Geno3D.
RESULTS: 1) Novel OA functions and biological roles were predicted, including roles in cell envelope formation, enzyme activities, immune response activities, negative regulation of B-cell activation, antigen processing, heme catabolism, endothelial cell differentiation, establishment of protein localization, melanin biosynthesis from tyrosine, regulation of blood pressure, response to light, and lung development. 2) Novel OA functional motifs were predicted, including N-Arg dibasic convertase cleavage site, NEC1/NEC2 cleavage site, peptide C-terminal amidation, glycosaminoglycan attachment site, and generic motif for N-glycosylation, and substrate recognition sites that interact with different cytosolic proteins, including cyclin, MAPK, Class III PDZ domains, GSK3, phosphorylase kinase, tyrosine-based sorting signal, and internalization signal. 3) OA's secondary and tertiary structural models were predicted.
CONCLUSIONS: bioinformatic structural analysis predicted that OA has three major structural domains: two helical structures on its termini and beta sheets as a sandwich-like structure in the middle. Several functional motifs have been predicted suggesting different modes for OA functions (receptor, ligand, and enzyme). Combined data from OA's expression array and function prediction data suggest that OA might play a role in several pathologic conditions, including hypertension, diabetes, and immune system disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179976

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  16 in total

1.  Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA.

Authors:  Juan Carlos Almagro; Gary L Gilliland; Felix Breden; Jamie K Scott; Devin Sok; Matthias Pauthner; Janice M Reichert; Gustavo Helguera; Raiees Andrabi; Robert Mabry; Mathieu Bléry; James E Voss; Juha Laurén; Lubna Abuqayyas; Stefan Barghorn; Eshel Ben-Jacob; James E Crowe; James S Huston; Stephen Albert Johnston; Eric Krauland; Fridtjof Lund-Johansen; Wayne A Marasco; Paul W H I Parren; Kai Y Xu
Journal:  MAbs       Date:  2014-03-03       Impact factor: 5.857

2.  Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy.

Authors:  Brian J Siroky; Hong Yin; Bradley P Dixon; Ryan J Reichert; Anna R Hellmann; Thiruvamoor Ramkumar; Zenta Tsuchihashi; Marlene Bunni; Joshua Dillon; P Darwin Bell; Julian R Sampson; John J Bissler
Journal:  Am J Physiol Renal Physiol       Date:  2014-06-11

Review 3.  Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target.

Authors:  Manisha Taya; Stephen R Hammes
Journal:  Steroids       Date:  2017-10-31       Impact factor: 2.668

4.  Comprehensive genomic analysis contrasting primary colorectal cancer and matched liver metastases.

Authors:  Akio Shiomi; Masatoshi Kusuhara; Takashi Sugino; Teiichi Sugiura; Keiichi Ohshima; Takeshi Nagashima; Kenichi Urakami; Masakuni Serizawa; Hideyuki Saya; Ken Yamaguchi
Journal:  Oncol Lett       Date:  2021-04-12       Impact factor: 2.967

5.  Comparison of bone morphogenetic protein-2 and osteoactivin for mesenchymal cell differentiation: effects of bolus and continuous administration.

Authors:  Oneida A Arosarena; Fabiola E Del Carpio-Cano; Raul A Dela Cadena; Mario C Rico; Emeka Nwodim; Fayez F Safadi
Journal:  J Cell Physiol       Date:  2011-11       Impact factor: 6.384

6.  Mutation in osteoactivin decreases bone formation in vivo and osteoblast differentiation in vitro.

Authors:  Samir M Abdelmagid; Joyce Y Belcher; Fouad M Moussa; Suzanne L Lababidi; Gregory R Sondag; Kimberly M Novak; Afif S Sanyurah; Nagat A Frara; Roshanak Razmpour; Fabiola E Del Carpio-Cano; Fayez F Safadi
Journal:  Am J Pathol       Date:  2014-01-23       Impact factor: 4.307

7.  Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.

Authors:  Seung-Beom Hong; HyoungBin Oh; Vladimir A Valera; Masaya Baba; Laura S Schmidt; W Marston Linehan
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

8.  Neuroimmune-vascular cells and their pathological disorders.

Authors:  Kirk J Mantione
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

9.  Expression and immunolocalization of Gpnmb, a glioma-associated glycoprotein, in normal and inflamed central nervous systems of adult rats.

Authors:  Jian-Jun Huang; Wen-Jie Ma; Shigeru Yokoyama
Journal:  Brain Behav       Date:  2012-03       Impact factor: 2.708

10.  Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.

Authors:  Gordana Maric; April An Rose; Matthew G Annis; Peter M Siegel
Journal:  Onco Targets Ther       Date:  2013-07-09       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.